Obinutuzumab plus fludarabine, cyclophosphamide feasible for fit CLL patients
06 Mar 2020
byJairia Dela Cruz
A regimen consisting of obinutuzumab plus fludarabine and cyclophosphamide achieves favourable outcomes with manageable toxicity in the treatment of chronic lymphocytic leukaemia (CLL) in physically fit adults, poised as an attractive first-line option in patients who are eligible for potent chemoimmunotherapy, according to data from the phase IIIb GREEN trial.
Obinutuzumab plus fludarabine, cyclophosphamide feasible for fit CLL patients
06 Mar 2020